The overarching goal of this study is to determine the role of chronic kidney disease and the
activation of the kallikrein-kinin system during hemodialysis on the development of
mitochondrial dysfunction; the investigators will measure mitochondrial function using the
gold standard method, 31-phosphorus magnetic resonance spectroscopy.
The investigators will test the hypothesis that endogenous bradykinin promotes mitochondrial
dysfunction in patients undergoing hemodialysis. The investigators will first perform a
randomized, placebo-controlled, double-blind, cross-over study measuring the effect of
Icatibant (HOE-140), a bradykinin B2 receptor blocker, on mitochondrial function.